This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
by Zacks Equity Research
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
by Sridatri Sarkar
TEM lifts its 2025 revenue and EBITDA outlook on strong Q1 results, key partnerships and testing expansion.
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
by Zacks Equity Research
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
by Zacks Equity Research
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
EXEL or ARGX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
What's Fueling Tempus AI's Explosive Sales Growth?
by Sridatri Sarkar
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
by Zacks Equity Research
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
by Zacks Equity Research
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
by Zacks Equity Research
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold
by Zacks Equity Research
EXEL, LYFT, and KGC see broker upgrades and strong 2025 earnings growth forecasts amid volatile market conditions.
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
by Zacks Equity Research
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
by Swayta Shah
EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
by Zacks Equity Research
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.